Literature DB >> 21278223

KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?

W Zhang, M J Labonte, H-J Lenz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21278223     DOI: 10.1093/annonc/mdq704

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter.

Authors:  Bríd M Ryan; Ana I Robles; Curtis C Harris
Journal:  Clin Cancer Res       Date:  2012-06-05       Impact factor: 12.531

2.  Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.

Authors:  Pei-Long Sun; Bing Li; Qi-Fa Ye
Journal:  Int J Colorectal Dis       Date:  2012-03-20       Impact factor: 2.571

3.  Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.

Authors:  Janne B Kjersem; Tone Ikdahl; Tormod Guren; Eva Skovlund; Halfdan Sorbye; Julian Hamfjord; Per Pfeiffer; Bengt Glimelius; Christian Kersten; Hiroko Solvang; Kjell M Tveit; Elin H Kure
Journal:  BMC Cancer       Date:  2012-11-20       Impact factor: 4.430

Review 4.  Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.

Authors:  Scott M Langevin; Brock C Christensen
Journal:  Cancer Med       Date:  2014-06-02       Impact factor: 4.452

Review 5.  Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.

Authors:  E K Morgen; H-J Lenz; D J Jonker; D Tu; G Milano; F Graziano; J Zalcberg; C S Karapetis; A Dobrovic; C J O'Callaghan; G Liu
Journal:  Pharmacogenomics J       Date:  2016-11-29       Impact factor: 3.245

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.